Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection

Zika virus (ZIKV), a mosquito-borne flavivirus with homology to Dengue virus (DENV), has become a public health emergency. By characterizing memory lymphocytes from ZIKV-infected patients, we dissected ZIKV-specific and DENV-cross-reactive immune responses. Antibodies to nonstructural protein 1 (NS1...

Full description

Bibliographic Details
Main Authors: Stettler, K, Beltramello, M, Espinosa, D, Graham, V, Cassotta, A, Bianchi, S, Vanzetta, F, Minola, A, Jaconi, S, Mele, F, Foglierini, M, Pedotti, M, Simonelli, L, Dowall, S, Atkinson, B, Percivalle, E, Simmons, C, Varani, L, Blum, J, Baldanti, F, Cameroni, E, Hewson, R, Harris, E, Lanzavecchia, A, Sallusto, F, Corti, D
Format: Journal article
Language:English
Published: American Association for the Advancement of Science 2016
Description
Summary:Zika virus (ZIKV), a mosquito-borne flavivirus with homology to Dengue virus (DENV), has become a public health emergency. By characterizing memory lymphocytes from ZIKV-infected patients, we dissected ZIKV-specific and DENV-cross-reactive immune responses. Antibodies to nonstructural protein 1 (NS1) were largely ZIKV-specific and were used to develop a serological diagnostic tool. In contrast, antibodies against E protein domain I/II (EDI/II) were cross-reactive and, although poorly neutralizing, potently enhanced ZIKV and DENV infection in vitro and lethally enhanced DENV disease in mice. Memory T cells against NS1 or E proteins were poorly cross-reactive, even in donors preexposed to DENV. The most potent neutralizing antibodies were ZIKV-specific and targeted EDIII or quaternary epitopes on infectious virus. An EDIII-specific antibody protected mice from lethal ZIKV infection, illustrating the potential for antibody-based therapy.